alendronate has been researched along with zoledronic acid in 226 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 59 (26.11) | 29.6817 |
| 2010's | 124 (54.87) | 24.3611 |
| 2020's | 43 (19.03) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L | 1 |
| Bruchhaus, I; Chan, JM; Croft, SL; Flessner, RM; Ghosh, S; Kemp, RG; Kendrick, H; Kobayashi, S; Lea, CR; Lewis, JC; Loftus, TC; Meints, GA; Nozaki, T; Oldfield, E; Tovian, ZS | 1 |
| Chan, JM; Flessner, R; Gómez, AO; González-Pacanowska, D; Jennings, S; Kosztowski, T; Kotsikorou, E; Meints, GA; Morita, CT; Odeh, S; Oldfield, E; Papapoulos, SE; Raker, AM; Sanders, JM; Schwerdtfeger, C; Song, Y; van Beek, ER; Wang, H; Zhang, Y | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG | 1 |
| Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Berlicki, Ł; Kafarski, P; Mucha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agamennone, M; Angelelli, M; Cellamare, S; Dimiccoli, V; Laghezza, A; Marobbio, CMT; Perna, F; Profilo, E; Purgatorio, R; Savino, S; Scala, R; Scilimati, A; Tolomeo, A; Tortorella, P; Toscano, A; Tricarico, D; Vitale, P | 1 |
| Abdelmagid, WM; Mahmoodi, N; Tanner, ME | 1 |
| Artyushin, OI; Brel, VK; Chuprov-Netochin, RN; Leonov, SV; Semenov, VV; Semenova, MN | 1 |
| Blangy, A; Cherfils, J; Ferrandez, Y; Gilardone, M; Morel, A; Morko, J; Mounier, L; Roche, D; Vääräniemi, J | 1 |
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Reid, IR | 2 |
| Gimsing, P; Jurlander, J; Nielsen, LB; Salomo, M | 1 |
| Cheng, YY; Huang, L; Kumta, SM; Lee, KM; Xu, JK; Zheng, MH | 1 |
| Hershman, D; Narayanan, R | 1 |
| Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M | 1 |
| Chapurlat, RD | 1 |
| Wallace, DJ | 1 |
| Cortizo, AM; McCarthy, AD; Vaisman, DN | 1 |
| Hande, K; Richardson, PG; Woo, SB | 1 |
| Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M | 1 |
| Bourgeois, SL; Goodell, GG; Sarathy, AP | 1 |
| Boulet, JM; Bunton, TE; Sellers, R; Walker, K; Whiteside, GT | 1 |
| Broumand, V; Fortin, M; Marx, RE; Sawatari, Y | 1 |
| Liel, Y | 1 |
| Eufinger, H; Hoefert, S | 1 |
| Robb-Nicholson, C | 1 |
| Alexander, RE | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E | 1 |
| Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E | 1 |
| Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
| Beamer, E; Kriegman, A; Lindsay, R; Saag, K; Zhou, W | 1 |
| Adera, M; Davis, J; Fiske, D; Kriegman, A; McClung, M; Miller, P; Minkoff, J; Recker, R; Zhou, W | 1 |
| Black, DM; Cummings, SR; Schwartz, AV | 1 |
| Kim, HW; Lee, JI | 1 |
| Camm, J; Karam, R; McClung, M | 1 |
| Zuber, MA | 1 |
| Mukherjee, S; Oldfield, E; Song, Y | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
| Awad, HA; Bechtold, CD; Bukata, SV; Hock, C; Ito, H; Nakamura, T; O'Keefe, RJ; Proulx, ST; Schwarz, EM; Tsutsumi, R | 1 |
| Dechow, PC; Kessler, HP; Naidu, A; Opperman, LA; Spears, R; Wright, JM | 1 |
| Cheng, JC; Wong, YK | 1 |
| Martens, MG; Shaw, H | 1 |
| Alon, US; Freundlich, M | 1 |
| Hochberg, MC | 1 |
| Arnol, V; Cortizo, AM; Felice, JI; Gangoiti, MV; McCarthy, AD | 1 |
| Kogan, R; Lehrer, S; Montazem, A; Pessin-Minsley, M; Pfail, J; Ramanathan, L; Stock, RG | 1 |
| Okazaki, R | 1 |
| Matsumoto, T | 1 |
| Yamashita, S | 2 |
| Bilezikian, JP | 1 |
| Elad, S; Hardan, I; Lazarovici, TS; Taicher, S; Yahalom, R; Yarom, N | 1 |
| Balasanian, E; Stanton, DC | 1 |
| Asuncion, F; Chiusaroli, R; Khatri, R; Kostenuik, P; Ohishi, M; Ominsky, M; Schipani, E; Thomas, C | 1 |
| Fakler, O; Gutwald, R; Liebehenschel, N; Sauerbier, S; Schmelzeisen, R; Wagner, K; Wongchuensoontorn, C | 1 |
| Ringe, JD | 1 |
| Baer, D; Han, MM; Hui, RL; Khoury, S; Liao, W; Liberty, D; Lo, JC; Martin, D; O'Ryan, FS | 1 |
| Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A | 1 |
| Allen, MR; Burr, DB | 1 |
| Allen, MR; Burr, DB; Feher, A; Fuchs, RK; Koivunemi, A; Koivunemi, M; Phipps, RJ; Reinwald, S | 1 |
| Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M | 1 |
| Henry, C; Jahnke, W | 1 |
| Bleasel, JF; Craig, SJ; Sullivan, L; Vaile, JH; Youssef, PP | 1 |
| Friedland, B; Treister, NS; Woo, SB | 1 |
| Bauer, DC; Black, DM; Boonen, S; Bucci-Rechtweg, C; Cauley, J; de Papp, A; Eastell, R; Genant, HK; Kelly, MP; Leung, PC; Palermo, L; Santora, A | 1 |
| Shane, E | 1 |
| Maricic, M | 1 |
| Arduino, PG; Broccoletti, R; Dalmasso, P; Mozzati, M; Scoletta, M | 1 |
| Adachi, JD; Adler, RA; Brown, J; Bucci-Rechtweg, C; Kendler, D; Mesenbrink, P; Miller, PD; Orwoll, ES; Readie, A; Weinstein, RS | 1 |
| Byard, S; Duer, MJ; Ironside, MS; Reid, DG | 1 |
| Dell, RM; Ott, SM; Silverman, SL | 1 |
| Azambuja, AA; Campos, MM; Cherubini, K; Maahs, MP; Salum, FG | 1 |
| Pozzi, S; Raje, N | 1 |
| Bouler, JM; Bujoli, B; Despas, C; Fayon, F; Gauthier, O; Janvier, P; Khairoun, I; Massiot, D; Mellier, C; Montavon, G; Rouillon, T; Schnitzler, V; Walcarius, A | 1 |
| Choi, SC; Kim, GT; Kim, KC; Kwon, YD | 1 |
| Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K | 1 |
| Pazianas, M | 1 |
| Articus, K; Gamerdinger, D; Hadji, P; Kann, PH; Loeffler, H; Möricke, R; Spieler, W; Ziller, V | 1 |
| Alloh Amichia, YC; Giumelli, B; Le Bars, P; Soueidan, A | 1 |
| Fehm, T; Kootz, B; Neubauer, H; Schott, S; Seeger, H; Wallwiener, M | 1 |
| Bauer, JS; Beck, N; Eitner, S; Kiefer, J; Stockmann, P; Wichmann, M | 1 |
| Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
| Curi, MM; Lascala, CA; Marques, MM; Martins, MA; Martins, MD; Migliorati, CA; Tenis, CA | 1 |
| Bartl, R | 1 |
| Marchetti, C; Montebugnoli, L; Moretti, F; Pelliccioni, GA | 1 |
| Bigi, A; Boanini, E; Fini, M; Gazzano, M; Torricelli, P | 1 |
| Açil, Y; Gassling, V; Möller, B; Niehoff, P; Rachko, K; Simon, MJ; Wiltfang, J | 1 |
| Articus, K; Baier, M; Gamerdinger, D; Hadji, P; Kann, PH; Moericke, R; Spieler, W; Ziller, V | 1 |
| Carter, CJ; Emory, CL; Ward, WG; Wilson, SC | 1 |
| Aro, HT; Heervä, E; Peltonen, J; Peltonen, S; Svedström, E; Väänänen, K | 1 |
| Bauer, DC; Schousboe, JT | 1 |
| Coburn, SP; Ericson, KL; Mumm, S; Sutton, RA; Whyte, MP | 1 |
| Al-Jamali, J; Joshi Oshero, J; Kovalova-Müller, A; Lemound, J; Metzger, MC; Sauerbier, S; Schmelzeisen, R; Veigel Merino, EA; Voss, PJ | 1 |
| Carson, DA; Cho, JS; Corr, M; Crain, B; Hayashi, T; Miller, LS; Norton, JT | 1 |
| Britton, C; Walsh, J | 1 |
| Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W | 1 |
| Aguirre, JI; Akhter, MP; Jorgensen, M; Kesavalu, L; Kimmel, DB; Pingel, JE; Williams, A; Wronski, TJ | 1 |
| Freiberger, JJ; Kraft, KH; McGraw, T; Moon, RE; Padilla-Burgos, R; Piantadosi, CA; Stolp, BW; Suliman, HB | 1 |
| Eriksen, EF; Halse, J | 1 |
| Brown, R; Cohen, A; Mancini, D; McMahon, DJ; Pandit, K; Restaino, S; Shane, E; Staron, RB; Stein, EM; Verna, EC; Young, P; Zhang, C | 1 |
| Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A | 1 |
| Abtahi, J; Agholme, F; Aspenberg, P; Sandberg, O | 1 |
| Abdel Aal, AB; Abdel Fattah, A; Abdellatif, EM; Baiomy, AA; El-Fekey, AA; Nassan, MA | 1 |
| Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, JA; Rössle, M; Schipmann, S; von Jackowski, J; Zemann, W | 1 |
| Chen, B; Li, Y; Xie, D; Xu, H; Yang, X | 1 |
| Chatterjee, S | 1 |
| Antunes, HS; de Oliveira, TF; Farias, DS; Sampieri, MB; Santos, PS; Tinôco-Araújo, JE; Zen Filho, EV | 1 |
| Magremanne, M; Reychler, H | 1 |
| Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N | 1 |
| Blauth, M; Ebner, HL; Genelin, K; Klawitter, M; Lindtner, RA; Manzl, C; Richards, PJ; Sitte, I; Tiaden, AN; von Rechenberg, B | 1 |
| Anitua, E; Begoña, L; Cobos, R; Orive, G; Serrano, AJ | 1 |
| Afsie, S; Al-Nammari, SS; Timothy, T | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Diab, DL; Watts, NB | 1 |
| Brennan, PA; Jenei, V; McLeod, NM; Moutasim, KA; Thomas, G | 1 |
| Colaço, B; Fernandes, MH; Garcia, M; Gomes, PS; Oliveira, R; Ribeiro, V | 1 |
| Nakamoto, T; Tanimoto, K; Zaman, MU | 1 |
| Bouxsein, ML; Brooks, DJ; Demay, MB; Louis, L; Zhu, ED | 1 |
| Chikazu, D; Hamada, H; Koizumi, T; Matsuo, A; Satomi, T | 1 |
| Bohgaki, M; Goto, M; Imoto, S; Matsumoto, E; Saigo, K | 1 |
| Al-Rifaiy, MQ; Almas, K; Javed, F; Vohra, F | 1 |
| Fabiny, A | 1 |
| Ross, JS | 1 |
| Barrett-Connor, E; Bauer, DC; Black, DM; Cauley, JA; Cummings, SR; Ensrud, KE; Hue, TF | 1 |
| Arroyo, JG; Freitag, SK; Lefebvre, DR; Mandeville, JT; Torun, N; Yonekawa, Y | 1 |
| Bhadada, SK; Bhansali, A; Dhiman, V; Mithal, A; Muthukrishnan, J; Sharma, DC; Sridhar, S | 1 |
| Cai, HF; Li, YT; Zhang, ZL | 1 |
| Edwards, S; Elford, C; Evans, BA; Fogelman, I; Frost, ML; Hampson, G; Ishtiaq, S; Sankaralingam, A | 1 |
| Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR | 1 |
| Choi, SC; Kim, EC; Kim, KC; Kim, MS; Kwon, YD; Yoo, JE | 1 |
| Jewett, A; Kanayama, K; Kaur, K; Kozlowska, A; McKenna, CE; Nishimura, I; Park, S; Park, SH; Sun, S; Tseng, HC | 1 |
| Adami, S; Gatti, D; Rossini, M; Viapiana, O | 1 |
| Eiken, P; Vestergaard, P | 1 |
| Cullen, N; Ferrero, A; Goldberg, A; Rose, B; Singh, D | 1 |
| Faasse, K; Fernandez, J; Grey, A; Horne, A; Kalluru, R; Petrie, KJ; Stephens, MH | 1 |
| Cunneen, TS; Goold, LA; Leibovitch, I; Martin, P; Pirbhai, A; Rajak, SN; Selva, D; Wilcsek, G | 1 |
| Akanle, OA; Al-Adhoubi, NK; Al-Bogami, MM; Alkhorayef, MA; Bystrom, J; Jawad, AS; Mageed, RA | 1 |
| Liu, L; Lu, Q; Ma, C; Tian, Y; Wang, R; Yin, F | 1 |
| Ataoğlu, B; Berkay, AF; Eren, TK; Kaptan, AY; Yapar, AE | 1 |
| Negredo, E; Warriner, AH | 1 |
| Ali, AA; Annett, S; Cunningham, R; Massey, AS; McBride, JW; McCaffrey, J; McCarthy, HO; McCrudden, CM; McErlean, EM; Migaud, ME; Pentlavalli, S; Redpath, P; Robson, T | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Li, Y; Sun, J; Tan, W; Wu, X; Zhou, L | 1 |
| Jiang, Y; Li, M; Liu, Y; Lv, F; Ma, DD; Wang, JY; Wang, O; Xia, WB; Xing, XP; Xu, XJ; Yu, W | 1 |
| Campbell, F; Davis, S; Gittoes, N; Goka, E; Martyn-St James, M; Rawdin, A; Sadler, S; Sanderson, J; Selby, P; Stevens, J; Stevenson, M; Strong, M; Wong, R | 1 |
| Blanco, R; Sánchez, A | 1 |
| Hagino, H; Moriwaki, K; Mouri, M | 1 |
| Jiang, LA; Leder, BZ; Lee, H; Tsai, JN | 1 |
| Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y | 1 |
| Albert, SG; Reddy, S | 1 |
| Liel, Y; Plakht, Y; Tailakh, MA | 1 |
| Dos Santos, GMT; Esquisatto, MAM; Felonato, M; Franzini, CM; Franzoni, JS; Mendonca, FAS; Santamaria, M; Santamaria, MP; Soares, FMP; Vedovello Filho, M; Zaniboni, E | 1 |
| Basso, FG; Cardoso, LM; de Souza Costa, CA; Hebling, J; Pansani, TN; Soares, DG | 1 |
| Intorcia, M; Karlsson, L; Mesterton, J; Overbeek, J; Ström, O; Tepie, MF | 1 |
| Clarke, B; Davies, JH; Fratzl-Zelman, N; Gafni, RI; Högler, W; Klaushofer, K; Rauch, F; Roschger, P; Sakka, S; Samuels, M; Saraff, V; Tebben, P | 1 |
| Kim, EC; Kwon, YD; Lee, JW; Park, J; Zhang, J | 1 |
| Filella, X; Florez, H; Guañabens, N; Mandelikova, S; Monegal, A; Peris, P | 1 |
| Al-Nawas, B; Jung, J; Kwon, YD; Pabst, AM; Park, JS; Righesso, L; Walter, C | 1 |
| Açil, Y; Arndt, ML; Ayna, M; Gülses, A; Naujokat, H; Wieker, H; Wiltfang, J | 1 |
| Jiang, Y; Li, L; Liu, Y; Lv, F; Song, Y; Wang, O; Xia, W; Xing, X; Xu, X | 1 |
| García-Martínez, O; Illescas-Montes, R; Manzano-Moreno, FJ; Melguizo-Rodríguez, L; Ramos-Torrecillas, J; Ruiz, C | 1 |
| Anastasilakis, AD; Makras, P; Polyzos, SA | 1 |
| Patntirapong, S; Poolgesorn, M | 1 |
| Arnett, TR; de Luna-Bertos, E; García-Martínez, O; Illescas-Montes, R; Manzano-Moreno, FJ; Ramos-Torrecillas, J; Ruiz, C | 1 |
| Chen, W; Huang, X; Lin, R; Wu, C; Wu, J; Zhang, X | 1 |
| Bauer, DC; Black, DM; Cosman, F; Eastell, R; Kim, TY; McNabb, BL; Schafer, AL | 1 |
| Brini, AT; Farronato, D; Farronato, G; Giannasi, C; Lombardi, G; Manfredi, B; Niada, S | 1 |
| Bazrafshan, A; Bordbar, M; Bozorgi, H; Haghpanah, S; Saki, F; Zekavat, OR | 1 |
| Chowdhury, A; Karamched, SR; Nosoudi, N; Parasaram, V; Parrish, J; Siclari, S | 1 |
| Brasure, M; Butler, M; Ensrud, KE; Fink, HA; Forte, ML; MacDonald, R; Nelson, VA; Olson, CM; Rosebush, CE; Schousboe, JT; Taylor, BC; Ullman, K; Wilt, TJ | 1 |
| Agarwala, S; Vijayvargiya, M | 1 |
| Chaurand-Lara, J; Facio-Umaña, JA; Mora-Pérez, J; Pacheco-Ruiz, L; Trejo-Campos, JL | 1 |
| Bauer, DC | 1 |
| Asch, AS; Kumar, G; Lightfoot, S; Madka, V; Mohammed, A; Pathuri, G; Rao, CV; Steele, VE; Zhang, Y | 1 |
| Min, N; Shi, L; Wang, F; Xue, QY | 1 |
| Costela-Ruiz, VJ; García-Martínez, O; Illescas-Montes, R; Manzano-Moreno, FJ; Melguizo-Rodriguez, L; Ramos-Torrecillas, J; Ruiz, C | 1 |
| Bastin, S; Gamble, GD; Horne, AM; Mihov, B; Reid, IR; Stewart, A | 1 |
| Kawashiri, T; Kobayashi, D; Shimazoe, T; Tokunaga, A | 1 |
| Cabete, J; Fernandes, C; Neves, JM | 1 |
| Catros, S; Châtel, C; Cloitre, A; Devoize, L; Foissac, F; Lesclous, P; Louvet, B; Roux, C | 1 |
| Ralston, SH | 1 |
| Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
| Niederer, R; Samalia, P; Sims, J | 1 |
| Basso, FG; Cardoso, LM; de Souza Costa, CA; Hebling, J; Pansani, TN; Ribeiro, IM; Rizzi, E | 1 |
| Cromer, SJ; D'Silva, KM; Desai, RJ; Kim, SC; Landon, J; Yu, EW | 1 |
| Arosio, M; Cairoli, E; Chiodini, I; Eller-Vainicher, C; Grassi, G; Palmieri, S | 1 |
| Crandall, CJ; Fujii, T; Ganz, DA; Mori, T | 1 |
| Chworos, A; Gostynski, B; Madaj, R; Pawlowska, R | 1 |
| Du, D; Gu, M; Jin, L; Xu, J; Yang, Z; Zhang, C; Zhao, S; Zhao, T; Zhao, W; Zheng, L | 1 |
| Al-Ahmad, A; Bock, A; Buhl, EM; Hellwig, E; Hölzle, F; Kniha, K; Modabber, A; Möhlhenrich, SC | 1 |
| Eastell, R; Gossiel, F; Peel, NFA; Ugur, A; Walsh, JS | 1 |
| Heitzer, M; Hölzle, F; Kniha, K; Modabber, A; Möhlhenrich, SC; Peters, F; Rink, L; Wolf, J | 1 |
| Colarossi, G; Driessen, A; Eschweiler, J; Maffulli, N; Migliorini, F; Oliva, F | 1 |
| González Macías, J; Olmos Martínez, JM | 1 |
| Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M | 1 |
| Chen, CH; Chen, WJ; Chen, YM; Chien, LN; Ku, CK; Li, CY; Lin, SY | 1 |
| Huang, J; Li, P; Li, Y; Wu, X | 1 |
| Cicchiello, S; De Ponte, FS; Lo Giudice, G; Marino, R; Mummolo, S; Nastro Siniscalchi, E; Scozzaro, C; Squillacioti, A | 1 |
| McConnell, M; Shieh, A | 1 |
| Chang, YF; Hsu, YH; Hwang, JS; Li, CC; Liang, FW; Wu, CH | 1 |
| Ai, W; Wang, Q; Yu, Q; Zeng, P | 1 |
| Ebeling, PR; Nerlekar, N; Rodríguez, AJ | 1 |
| Lane, JM; Levin, JE; Nieves, JW; Tutaworn, T; Wang, Z; Yoo, JE | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 1 |
| Chang, AB; Conwell, LS; Jeffery, TC | 1 |
| Gates, M; Hartling, L; Nuspl, M; Pillay, J; Vandermeer, B; Wingert, A | 1 |
| Arora, T; Balasubramanian, A; Bradbury, BD; Curtis, JR; Kim, M; Lin, TC; O'Kelly, J; Spangler, L; Stad, RK; Zhao, H | 1 |
| Amigues, C; Breuil, V; Drici, MD; Fresse, A; Gauthier, S; Roux, CH; Vieillard, MH | 1 |
| Chen, HM; Fu, SH; Hsu, CC; Hwang, JS; Lee, CC; Lin, JW; Lin, SC; Wang, CY; Wu, CH; Yang, RS | 1 |
| Li, YF; Luo, C; Qu, XL; Sheng, ZF; Tian, L; Wang, QY; Xu, LL; Yang, YY; Yue, C | 1 |
| Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR | 1 |
| Budzinska, A; Galganski, L; Jarmuszkiewicz, W | 1 |
| Bastounis, A; Bishop, S; Corp, N; Gittoes, N; Griffin, J; Langley, T; Leonardi-Bee, J; Narayanasamy, MJ; Paskins, Z; Sahota, O | 1 |
| Alves Coelho, MC; Brasil d'Alva, C; Gehrke, B; Madeira, M | 1 |
51 review(s) available for alendronate and zoledronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Structure-Activity Relationship; Zoledronic Acid | 2003 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid | 2004 |
Rapid prevention of vertebral fractures associated with osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2005 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
[Bisphosphonates and other new therapeutic agents for the treatmednt of osteogenesis imperfecta].
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Child, Preschool; Clinical Trials as Topic; Denosumab; Diphosphonates; Drug Administration Schedule; Genetic Therapy; Humans; Imidazoles; Infusions, Intravenous; Osteogenesis Imperfecta; Pamidronate; RANK Ligand; Severity of Illness Index; Stem Cell Transplantation; Teriparatide; Zoledronic Acid | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
[Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Humans; Imidazoles; Infant; Infusions, Intravenous; Osteogenesis Imperfecta; Pamidronate; Severity of Illness Index; Zoledronic Acid | 2010 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Monitoring, Physiologic; Osteoporotic Fractures; Raloxifene Hydrochloride; Wound Healing; Zoledronic Acid | 2012 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Disease Susceptibility; Etidronic Acid; Female; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Models, Biological; Neoplasms; Osteitis; Osteoporosis; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2012 |
Osteopathology associated with bone resorption inhibitors - which role does Actinomyces play? A presentation of 51 cases with systematic review of the literature.
Topics: Actinomyces; Actinomycosis; Adult; Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Biopsy; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; RANK Ligand; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2013 |
Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2013 |
A Surgeon's guide to advances in the pharmacological management of acute Charcot neuroarthropathy.
Topics: Alendronate; Alkaline Phosphatase; Arthropathy, Neurogenic; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Humans; Hydroxyproline; Imidazoles; Immobilization; Insulin-Like Growth Factor I; Pamidronate; Randomized Controlled Trials as Topic; RANK Ligand; Skin Temperature; Zoledronic Acid | 2013 |
Postmenopausal osteoporosis.
Topics: Accidental Falls; Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium; Denosumab; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Risk Reduction Behavior; Teriparatide; Vitamin D; Zoledronic Acid | 2013 |
Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Implants; Dental Restoration Failure; Diphosphonates; Female; Ibandronic Acid; Imidazoles; Osseointegration; Osteoporosis; Ovariectomy; Surface Properties; Zoledronic Acid | 2014 |
A Case Series and Review of Bisphosphonate-associated Orbital Inflammation.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Orbital Cellulitis; Orbital Pseudotumor; Remission, Spontaneous; Retrospective Studies; Zoledronic Acid | 2016 |
Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Diphosphonates; Female; Femoral Fractures; Humans; Imidazoles; India; Middle Aged; Osteoporosis; Prodromal Symptoms; Retrospective Studies; Zoledronic Acid | 2014 |
Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Humans; Imidazoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2015 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid | 2015 |
Treatment of osteoporosis after alendronate or risedronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2016 |
Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Orbital Cellulitis; Orbital Myositis; Pamidronate; Radiography; Retrospective Studies; Zoledronic Acid | 2015 |
Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Infusions, Intravenous; Macular Edema; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome; Uveitis; Zoledronic Acid | 2016 |
Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients.
Topics: Alendronate; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Diphosphonates; HIV Infections; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Topics: Alendronate; Bone Density Conservation Agents; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Models, Econometric; Osteoporotic Fractures; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Social Work; State Medicine; United Kingdom; Zoledronic Acid | 2016 |
Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Crohn Disease; Diphosphonates; Humans; Imidazoles; Network Meta-Analysis; Risedronic Acid; Sodium Fluoride; Zoledronic Acid | 2017 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Teriparatide; Zoledronic Acid | 2017 |
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Teriparatide; Zoledronic Acid | 2018 |
Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.
Topics: Absorptiometry, Photon; Alendronate; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Femur Neck; Humans; Lumbar Vertebrae; Male; Osteoporosis; Pelvic Bones; Prostatic Neoplasms; Zoledronic Acid | 2018 |
Bisphosphosphonate-calcium phosphate cement composite and its properties.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Calcium Phosphates; Diphosphonates; Drug Carriers; Drug Delivery Systems; Etidronic Acid; Humans; Pamidronate; Zoledronic Acid | 2019 |
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Administration Schedule; Duration of Therapy; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2019 |
Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Network Meta-Analysis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Secondary Prevention; Zoledronic Acid | 2019 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2022 |
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.
Topics: Adrenal Cortex Hormones; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Denosumab; Etidronic Acid; Glucocorticoids; Humans; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2022 |
Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Hydroxyapatites; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Zoledronic Acid | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2023 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female; Fractures, Bone; Humans; Musculoskeletal Pain; Osteoporosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2023 |
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Topics: Adult; Alendronate; Canada; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Male; Middle Aged; Osteoporotic Fractures; Primary Health Care; Primary Prevention; Risedronic Acid; Systematic Reviews as Topic; Zoledronic Acid | 2023 |
Long-term consequences of osteoporosis therapy with bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Quality of Life; Zoledronic Acid | 2023 |
18 trial(s) available for alendronate and zoledronic acid
| Article | Year |
|---|---|
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Collagen Type I; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Peptides; Postmenopause; Surveys and Questionnaires; Time Factors; Zoledronic Acid | 2007 |
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
Topics: Administration, Oral; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Tolerance; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Peptide Fragments; Peptides; Procollagen; Safety; Zoledronic Acid | 2007 |
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Treatment Outcome; Zoledronic Acid | 2010 |
Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Zoledronic Acid | 2012 |
A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Alendronate; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Chlorhexidine; Diphosphonates; Drug Combinations; Female; Follow-Up Studies; Humans; Imidazoles; Male; Metronidazole; Middle Aged; Mouthwashes; Oral Hygiene; Pain Measurement; Pamidronate; Prospective Studies; Salicylates; Terpenes; Treatment Outcome; Zoledronic Acid | 2011 |
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drugs, Generic; Female; Health Status; Humans; Imidazoles; Infusions, Intravenous; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Preference; Psychometrics; Quality of Life; Zoledronic Acid | 2012 |
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Gingiva; Humans; Hyperbaric Oxygenation; Imidazoles; Male; Multiple Myeloma; Osteoporosis; Pain Management; Pamidronate; Prospective Studies; Quality of Life; Treatment Outcome; Wound Healing; Zoledronic Acid | 2012 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Heart Transplantation; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Placebos; Postoperative Care; Postoperative Complications; Zoledronic Acid | 2012 |
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; Incidence; Infusions, Intravenous; Middle Aged; Odds Ratio; Postmenopause; Risk; Zoledronic Acid | 2014 |
The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.
Topics: Alendronate; Angiopoietin-1; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Cell Line; Cell Line, Tumor; Culture Media, Conditioned; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Humans; Imidazoles; Mice; Middle Aged; Osteoblasts; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2015 |
3-D bone models to improve treatment initiation among patients with osteoporosis: A randomised controlled pilot trial.
Topics: Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Imidazoles; Male; Models, Anatomic; Osteoporosis; Patient Acceptance of Health Care; Patient Education as Topic; Pilot Projects; Zoledronic Acid | 2016 |
Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Prospective Studies; Zoledronic Acid | 2016 |
THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Osteogenesis Imperfecta; Outcome Assessment, Health Care; Young Adult; Zoledronic Acid | 2016 |
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Teriparatide; Zoledronic Acid | 2017 |
ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Topics: Adolescent; Alendronate; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Osteogenesis Imperfecta; Time Factors; Treatment Outcome; Zoledronic Acid | 2018 |
Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Female; Femur Neck; Humans; Osteogenesis; Zoledronic Acid | 2019 |
Comparative effectiveness of alendronate and zoledronic acid on bone mass improvement in transfusion-dependent thalassemia patients.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alendronate; Blood Transfusion; Bone and Bones; Bone Density; Bone Density Conservation Agents; Female; Humans; Male; Middle Aged; Thalassemia; Young Adult; Zoledronic Acid | 2019 |
Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial.
Topics: Age Distribution; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Weight Loss; Zoledronic Acid | 2020 |
157 other study(ies) available for alendronate and zoledronic acid
| Article | Year |
|---|---|
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid | 2002 |
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Topics: Animals; Antimalarials; Antiprotozoal Agents; Cell Line; Cricetinae; Diphosphonates; Entamoeba histolytica; Entamoebiasis; Humans; In Vitro Techniques; Liver Abscess; Malaria; Mice; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship | 2004 |
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium; Diphosphonates; Geranyltranstransferase; Humans; In Vitro Techniques; Leishmania major; Metatarsal Bones; Mice; Models, Molecular; Pyridinium Compounds; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; Trypanocidal Agents | 2005 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2008 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
Topics: Amino Acid Motifs; Chemistry, Pharmaceutical; Humans; Organophosphonates; Phosphinic Acids | 2011 |
Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
Topics: Animals; Calcification, Physiologic; Cell Line; Diphosphonates; Enzyme Inhibitors; Geranylgeranyl-Diphosphate Geranylgeranyltransferase; Geranyltranstransferase; Humans; Mice; Molecular Docking Simulation; Osteoclasts; Osteogenesis; RAW 264.7 Cells | 2018 |
A guanidinium-based inhibitor of a type I isopentenyl diphosphate isomerase.
Topics: Carbon-Carbon Double Bond Isomerases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Escherichia coli; Geranyltranstransferase; Guanidine; Hemiterpenes; Humans; Molecular Structure; Structure-Activity Relationship | 2020 |
Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility.
Topics: Acetamides; Animals; Antimitotic Agents; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Humans; Indoles; Sea Urchins; Solubility | 2020 |
Novel 2,7-Diazaspiro[4,4]nonane Derivatives to Inhibit Mouse and Human Osteoclast Activities and Prevent Bone Loss in Ovariectomized Mice without Affecting Bone Formation.
Topics: Alkanes; Animals; Bone Resorption; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred C57BL; Osteoclasts; Osteogenesis; Ovariectomy | 2020 |
How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics.
Topics: Alendronate; Alkyl and Aryl Transferases; Apoptosis; Blotting, Western; Diphosphonates; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Geranyltranstransferase; Humans; Imidazoles; Linear Models; Multiple Myeloma; Polymerase Chain Reaction; Treatment Failure; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
Topics: Alendronate; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Diphosphonates; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Giant Cell Tumor of Bone; Humans; Imidazoles; In Situ Nick-End Labeling; Osteoclasts; Pamidronate; Stromal Cells; Tumor Cells, Cultured; Zoledronic Acid | 2004 |
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Topics: Alendronate; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Diphosphonates; Drug Screening Assays, Antitumor; Germany; Humans; Ibandronic Acid; Imidazoles; Neuroblastoma; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2005 |
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diphosphonates; Imidazoles; Isoenzymes; Magnesium; Osteoblasts; Osteosarcoma; Pamidronate; Rats; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2005 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Hyperalgesia; Imidazoles; Ligation; Male; Neuralgia; Physical Stimulation; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Stress, Mechanical; Treatment Outcome; Zoledronic Acid | 2006 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alendronate; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Drug Costs; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2005 |
[Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].
Topics: Aged; Alendronate; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouth Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Plasmacytoma; Radiography, Panoramic; Risk Factors; Zoledronic Acid | 2005 |
By the way, doctor. I've heard that taking Fosamax for a long time causes the jawbone to deteriorate. Do you know anything about this?
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoclasts; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Relationship between periodontal disease and systemic diseases.
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Dental Implantation, Endosseous; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Geranyltranstransferase; Humans; Imidazoles; Male; Multicenter Studies as Topic; Osteitis Deformans; Osteoporosis, Postmenopausal; Patient Compliance; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Surveys and Questionnaires; Time Factors; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Osteonecrosis; Pamidronate; Tomography, X-Ray Computed; Zoledronic Acid | 2007 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Curettage; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Radiography; Time Factors; Zoledronic Acid | 2006 |
Alendronate and atrial fibrillation.
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Zoledronic Acid | 2007 |
Re: 'A single zoleledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density' by Saag et al.
Topics: Administration, Oral; Alendronate; Biomarkers; Bone Density; Bone Resorption; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Time Factors; Zoledronic Acid | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2007 |
[Osteoporosis and bisphosphonates].
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risk Assessment; Zoledronic Acid | 2007 |
NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model.
Topics: Alendronate; Biochemistry; Bone and Bones; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Humans; Hydrogen; Imidazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Pamidronate; Protein Structure, Tertiary; Risedronic Acid; Zoledronic Acid | 2008 |
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Image Processing, Computer-Assisted; Imidazoles; Mice; Osteoclasts; Osteolysis; Osteoprotegerin; Polyethylene; Prosthesis Failure; Skull; Surface Properties; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
The effects of bisphosphonates on osteoblasts in vitro.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Cell Survival; Cells, Cultured; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Imidazoles; Interleukin-6; Osteoblasts; RANK Ligand; Rats; Transforming Growth Factor beta1; Zoledronic Acid | 2008 |
Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Tooth Extraction; Zoledronic Acid | 2008 |
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Imidazoles; Medication Adherence; Osteoporosis; Physician-Patient Relations; Risedronic Acid; Risk Factors; Zoledronic Acid | 2008 |
Bisphosphonates in children with hypercalciuria and reduced bone mineral density.
Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Child; Creatinine; Diphosphonates; Female; Humans; Hypercalciuria; Imidazoles; Male; Phosphorus; Retrospective Studies; Zoledronic Acid | 2008 |
Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
Topics: 3T3 Cells; Alendronate; Animals; Bone Density Conservation Agents; Calcium; Calcium Channels, L-Type; Cattle; Cell Line; Diabetes Complications; Diphosphonates; Dose-Response Relationship, Drug; Glycation End Products, Advanced; Imidazoles; Mice; Osteoblasts; Osteoporosis; Pamidronate; Rats; Reactive Oxygen Species; Serum Albumin, Bovine; Time Factors; Zoledronic Acid | 2008 |
Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cysteine Endopeptidases; Diphosphonates; Female; Humans; Imidazoles; Male; Mandibular Diseases; Matrix Metalloproteinase 2; Maxillary Diseases; Osteocalcin; Osteonecrosis; Parathyroid Hormone; Peptides; Vitamin D; Zoledronic Acid | 2009 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Minimally Invasive Surgical Procedures; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Risk Factors; Smoking; Time Factors; Treatment Outcome; Wound Healing; Zoledronic Acid | 2009 |
Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Treatment Outcome; Zoledronic Acid | 2009 |
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Humans; Hyperparathyroidism; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Porosity; Primary Myelofibrosis; Receptor, Parathyroid Hormone, Type 1; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.
Topics: Administration, Oral; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Fracture Fixation, Internal; Fractures, Spontaneous; Humans; Imidazoles; Injections, Intravenous; Male; Mandibular Diseases; Mandibular Fractures; Middle Aged; Osteonecrosis; Palliative Care; Tooth Extraction; Zoledronic Acid | 2009 |
[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Zoledronic Acid | 2009 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Technetium Compounds; Zoledronic Acid | 2009 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Diphosphonates; Female; Humans; Imidazoles; Inflammation; Jaw; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Microscopy, Electron, Scanning; Middle Aged; Osteomyelitis; Osteonecrosis; Osteoporosis; Osteoradionecrosis; Pamidronate; Time Factors; Zoledronic Acid | 2010 |
Mandibular necrosis in beagle dogs treated with bisphosphonates.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Cell Death; Cell Survival; Coloring Agents; Diphosphonates; Disease Models, Animal; Dogs; Female; Haversian System; Imidazoles; L-Lactate Dehydrogenase; Mandibular Diseases; Osteocytes; Osteonecrosis; Ribs; Rosaniline Dyes; Time Factors; Zoledronic Acid | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Steroids; Teriparatide; Vitamin D; Zoledronic Acid | 2009 |
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Imidazoles; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Risedronic Acid; Zoledronic Acid | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid | 2010 |
An in vitro assay to measure targeted drug delivery to bone mineral.
Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid | 2010 |
Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Zoledronic Acid | 2011 |
Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphosphonates; Dry Socket; Female; Humans; Imaging, Three-Dimensional; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Oroantral Fistula; Osteonecrosis; Osteosclerosis; Pamidronate; Radiography, Dental, Digital; Radiography, Panoramic; Tooth Socket; Zoledronic Acid | 2010 |
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Topics: Alendronate; Bone Density Conservation Agents; Confidence Intervals; Diphosphonates; Female; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid | 2010 |
Evolving data about subtrochanteric fractures and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2010 |
Intravenous zoledronic acid: what are the indications for male osteoporosis?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Male; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Risk Factors; Testosterone; Zoledronic Acid | 2010 |
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.
Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chronic Disease; Clindamycin; Cohort Studies; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Jaw Diseases; Male; Oral Fistula; Osteonecrosis; Pamidronate; Penicillins; Prospective Studies; Remission Induction; Risk Factors; Smoking; Tooth Extraction; Treatment Outcome; Wound Healing; Zoledronic Acid | 2010 |
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Crystallization; Diphosphonates; Horses; Imidazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Pamidronate; Structure-Activity Relationship; Technology, Pharmaceutical; Zoledronic Acid | 2010 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Imidazoles; Incidence; Time Factors; Zoledronic Acid | 2010 |
Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Imidazoles; Jaw; Osteonecrosis; Random Allocation; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid | 2011 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteonecrosis; Risk Factors; Zoledronic Acid | 2010 |
Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic hip fractures: critical influence of the drug introduction mode on the in vitro cement properties.
Topics: Adsorption; Alendronate; Apatites; Bone Cements; Calcium Phosphates; Dielectric Spectroscopy; Diphosphonates; Hip Fractures; Imidazoles; Magnetic Resonance Spectroscopy; Osteoporotic Fractures; Time Factors; Zoledronic Acid | 2011 |
The effects of topical application of bisphosphonates on replanted rat molars.
Topics: Administration, Topical; Alendronate; Animals; Bone Density Conservation Agents; Citric Acid; Dental Cementum; Dentin; Desiccation; Diphosphonates; Etidronic Acid; Imidazoles; Male; Molar; Rats; Rats, Sprague-Dawley; Root Canal Therapy; Root Resorption; Temperature; Time Factors; Tooth Replantation; Tooth Root; Tooth Socket; Zoledronic Acid | 2010 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
[Prosthetic rehabilitation after osteonecrosis of the jaws due to histiocytosis X and treatment with bisphosphonates apropos of a case].
Topics: Adult; Alendronate; Bone Density Conservation Agents; Denture Design; Denture, Partial, Fixed; Denture, Partial, Temporary; Diphosphonates; Female; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Jaw, Edentulous, Partially; Mandibular Diseases; Osteonecrosis; Pamidronate; Risk Factors; Tooth Extraction; Zoledronic Acid | 2010 |
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Alendronate; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Imidazoles; Inhibitory Concentration 50; Ovarian Neoplasms; Reference Standards; Zoledronic Acid | 2012 |
Awareness and education of patients receiving bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Dental Care; Dentist-Patient Relations; Dentists; Diphosphonates; Drug Labeling; Female; Gastrointestinal Diseases; Health Knowledge, Attitudes, Practice; Health Literacy; Humans; Imidazoles; Injections, Intravenous; Interprofessional Relations; Male; Middle Aged; Osteoporosis; Patient Education as Topic; Physician-Patient Relations; Physicians; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2012 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lasers, Semiconductor; Low-Level Light Therapy; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Platelet-Rich Plasma; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid | 2012 |
[Inflammation of the jaws during treatment with bisphosphonates].
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Approval; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Opportunistic Infections; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Risk Factors; Zoledronic Acid | 2011 |
The effect of zoledronate-hydroxyapatite nanocomposites on osteoclasts and osteoblast-like cells in vitro.
Topics: Alendronate; Cell Differentiation; Cell Proliferation; Cells, Cultured; Diphosphonates; Durapatite; Humans; Imidazoles; Microscopy, Electron, Scanning; Nanocomposites; Nanoparticles; Osteoblasts; Osteoclasts; X-Ray Diffraction; Zoledronic Acid | 2012 |
The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells.
Topics: Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Collagen Type I; Coloring Agents; Diphosphates; Diphosphonates; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Follow-Up Studies; Gingiva; Humans; Imidazoles; Osteoblasts; Osteocalcin; Osteosarcoma; Pamidronate; Tetrazolium Salts; Thiazoles; Zoledronic Acid | 2012 |
Femoral stress fractures associated with long-term bisphosphonate treatment.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Female; Femoral Fractures; Fractures, Stress; Humans; Imidazoles; Length of Stay; Male; Middle Aged; Radiography; Retrospective Studies; Zoledronic Acid | 2012 |
Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Neurofibromatosis 1; Osteoclasts; Osteoporosis; Zoledronic Acid | 2012 |
"Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia.
Topics: Alendronate; Diphosphonates; Female; Femoral Fractures; Humans; Hypophosphatasia; Imidazoles; Middle Aged; Zoledronic Acid | 2012 |
Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Debridement; Dental Care; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Oral Fistula; Osteotomy; Postoperative Complications; Retrospective Studies; Surgical Flaps; Surgical Wound Dehiscence; Suture Techniques; Treatment Outcome; Zoledronic Acid | 2012 |
Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1.
Topics: Alendronate; Animals; Chemotaxis; Clodronic Acid; Diphosphonates; Imidazoles; Interleukin-1alpha; Interleukin-1beta; Leukocytes; Mast Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains; Myeloid Differentiation Factor 88; Neutrophils; Pamidronate; Peritonitis; Receptors, Interleukin-1; Zoledronic Acid | 2012 |
Paget disease of bone - an update.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2012 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid | 2013 |
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.
Topics: Alendronate; Animals; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Count; Diphosphonates; Dose-Response Relationship, Drug; Imidazoles; Mandible; Osteoclasts; Osteocytes; Osteogenesis; Periodontitis; Sigmodontinae; Zoledronic Acid | 2012 |
[When should bisphosphonate treatment be discontinued?].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Risk Factors; Zoledronic Acid | 2012 |
Effect of local vs. systemic bisphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw.
Topics: Administration, Topical; Alendronate; Animals; Anti-Inflammatory Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Coated Materials, Biocompatible; Dental Implantation, Endosseous; Dental Implants, Single-Tooth; Dental Prosthesis Retention; Dental Stress Analysis; Dexamethasone; Diphosphonates; Drug Delivery Systems; Imidazoles; Injections, Intravenous; Male; Maxilla; Osseointegration; Rats; Rats, Sprague-Dawley; Surface Properties; Tooth Socket; X-Ray Microtomography; Zoledronic Acid | 2013 |
Experimental comparison of the effects of locally administered zoledronic acid and alendronate on the rate of mandibular distraction osteogenesis in dogs.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone Density; Diphosphonates; Dogs; Imidazoles; Mandible; Osteogenesis; Osteogenesis, Distraction; Osteotomy; Random Allocation; Zoledronic Acid | 2014 |
Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Evaluation, Preclinical; Female; Femur; Humans; Imidazoles; Materials Testing; Orthopedic Fixation Devices; Osseointegration; Osteoporosis, Postmenopausal; Ovariectomy; Prostheses and Implants; Rats; Stress, Mechanical; Thiophenes; Tibia; Titanium; Zoledronic Acid | 2013 |
Atypical femoral fractures associated with long-term bisphosphonate use.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Humans; Imidazoles; Radiography; Zoledronic Acid | 2013 |
Clinical and image findings in bisphosphonate-related osteonecrosis of the jaws.
Topics: Adult; Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Debridement; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Postoperative Complications; Radiography, Panoramic; Tomography, X-Ray Computed; Tooth Extraction; Zoledronic Acid | 2013 |
Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Alendronate; Antioxidants; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Pentoxifylline; Tocopherols; Tooth Extraction; Zoledronic Acid | 2014 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid | 2013 |
Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Cell Differentiation; Cells, Cultured; Diphosphonates; Female; Humans; Imidazoles; Mesenchymal Stem Cells; Osteogenesis; Osteopontin; Osteoporosis, Postmenopausal; Zoledronic Acid | 2014 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
In vitro effect of bisphosphonates on oral keratinocytes and fibroblasts.
Topics: Alendronate; Bone Density Conservation Agents; Cell Movement; Cell Proliferation; Cells, Cultured; Clodronic Acid; Coculture Techniques; Diphosphonates; Fetus; Fibroblasts; Foreskin; Humans; Imidazoles; Keratinocytes; Male; Mouth Mucosa; Zoledronic Acid | 2014 |
Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells.
Topics: Alendronate; Alkaline Phosphatase; Antigens, CD; Bone Density Conservation Agents; Cadherins; Cell Differentiation; Cell Proliferation; Cell Shape; Cells, Cultured; Coculture Techniques; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Gene Expression; Humans; Imidazoles; Mesenchymal Stem Cells; Microvessels; Osteoblasts; Osteogenesis; Platelet Endothelial Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor; Zoledronic Acid | 2014 |
A retrospective study of digital subtraction technique to detect sclerotic changes in alveolar bone on intraoral radiographs of bisphosphonate-treated patients.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alveolar Process; Anatomic Landmarks; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandibular Diseases; Middle Aged; Osteosclerosis; Radiography, Bitewing; Radiography, Dental, Digital; Retrospective Studies; Subtraction Technique; Zoledronic Acid | 2013 |
Effect of bisphosphonates on the rapidly growing male murine skeleton.
Topics: Alendronate; Animals; Apoptosis; Biomechanical Phenomena; Bone and Bones; Bone Development; Bone Resorption; Chondrocytes; Clodronic Acid; Diphosphonates; Hypertrophy; Imidazoles; Male; Mice; Mice, Inbred C57BL; Pamidronate; Phenotype; X-Ray Microtomography; Zoledronic Acid | 2014 |
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Early Diagnosis; Etidronic Acid; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Osteolysis; Osteosclerosis; Pamidronate; Risedronic Acid; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
[Effects of four bisphosphonates on macrophage phagocytosis: quantitative measurement by flow cytometry using high-fluorescence particles and human monocytic cell line THP-1].
Topics: Alendronate; Apoptosis; Bone Density Conservation Agents; Cell Line; Diphosphonates; Flow Cytometry; Fluorescent Dyes; Humans; Imidazoles; Macrophages; Pamidronate; Phagocytosis; Zoledronic Acid | 2014 |
Ask the doctor. I've had osteoporosis for several years, and I've been taking alendronate (Fosamax) once a week. I wasn't very good at remembering to take it regularly, so my doctor recently recommended that I start on once-a-year infusions of zoledronic
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Health Behavior; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Zoledronic Acid | 2014 |
Randomized clinical trials and observational studies are more often alike than unlike.
Topics: Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Could zoledronic acid prevent root resorption in replanted rat molar?
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Imidazoles; Rats; Rats, Sprague-Dawley; Root Resorption; Tooth Replantation; Zoledronic Acid | 2015 |
Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation.
Topics: Alendronate; Animals; Apoptosis; Bone Marrow; Cell Communication; Cell Differentiation; Diphosphonates; Female; Gingiva; Humans; Imidazoles; Killer Cells, Natural; Macrophages; Mice; Mice, Inbred C57BL; Monocytes; Osteoclasts; Zoledronic Acid | 2015 |
Bone Marrow Edema Syndrome of the Foot and Ankle: Mid- to Long-Term Follow-up in 18 Patients.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Marrow Diseases; Diphosphonates; Edema; Female; Follow-Up Studies; Foot Diseases; Foot Orthoses; Humans; Imidazoles; Immobilization; Male; Middle Aged; Pain Management; Retrospective Studies; Zoledronic Acid | 2016 |
Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Zoledronic Acid | 2015 |
Atypical femoral fracture following zoledronic acid treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Femoral Fractures; Fracture Fixation; Humans; Ibandronic Acid; Imidazoles; Magnetic Resonance Imaging; Osteoporosis; Treatment Outcome; Withholding Treatment; Zoledronic Acid | 2016 |
Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Cell Line, Tumor; Cell Survival; Diphosphonates; Humans; Imidazoles; Male; Mice; Nanoparticles; Peptides; Prostatic Neoplasms; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Fractures, Spontaneous; Hip Fractures; Humans; Imidazoles; Osteoporosis, Postmenopausal; Radiography; Zoledronic Acid | 2017 |
Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Hip Fractures; Humans; Imidazoles; Injections, Intravenous; Japan; Models, Econometric; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality-Adjusted Life Years; Sensitivity and Specificity; Spinal Fractures; Zoledronic Acid | 2017 |
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Deprescriptions; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Time Factors; Treatment Failure; Zoledronic Acid | 2017 |
Zoledronic acid and alendronate sodium and the implications in orthodontic movement.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Diphosphonates; Imidazoles; Male; Rats; Rats, Wistar; Tooth Movement Techniques; Zoledronic Acid | 2017 |
Influence of bisphosphonates on the adherence and metabolism of epithelial cells and gingival fibroblasts to titanium surfaces.
Topics: Alendronate; Cell Adhesion; Cell Adhesion Molecules; Cell Survival; Cells, Cultured; Diphosphonates; Epidermal Growth Factor; Epithelial Cells; Fibroblasts; Gingiva; Humans; Imidazoles; Immunoglobulins; Materials Testing; Microscopy, Confocal; Microscopy, Electron, Scanning; Surface Properties; Titanium; Zoledronic Acid | 2018 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Netherlands; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Registries; Risedronic Acid; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2017 |
Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome.
Topics: Adolescent; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Case-Control Studies; Child; Diphosphonates; Female; Hajdu-Cheney Syndrome; Humans; Imidazoles; Male; Mutation; Osteoclasts; Receptor, Notch2; Zoledronic Acid | 2017 |
Bisphosphonates hinder osteoblastic/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells.
Topics: Adult; Alendronate; Alkaline Phosphatase; Blotting, Western; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Diphosphonates; Female; Humans; Male; Maxillary Sinus; Osteoblasts; Osteoclasts; RANK Ligand; Real-Time Polymerase Chain Reaction; Sp7 Transcription Factor; Stem Cells; Zoledronic Acid | 2018 |
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibrous Dysplasia of Bone; Humans; Male; Middle Aged; Osteomalacia; Pamidronate; Phosphorus; Reference Values; Young Adult; Zoledronic Acid | 2018 |
Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro.
Topics: Administration, Oral; Alendronate; Apoptosis; Cell Movement; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Fibroblasts; Humans; Ibandronic Acid; In Vitro Techniques; Infusions, Intravenous; Osteoblasts; Zoledronic Acid | 2018 |
Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.
Topics: Alendronate; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Cytotoxins; Diphosphonates; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression; Gingiva; Humans; Imidazoles; Inflammation; Osteoblasts; Osteosarcoma; Real-Time Polymerase Chain Reaction; Zoledronic Acid | 2018 |
Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 7; Cell Differentiation; Cell Proliferation; Clodronic Acid; Diphosphonates; Gene Expression; Humans; Imidazoles; Osteoblasts; Osteoclasts; Primary Cell Culture; Transforming Growth Factor beta1; Zoledronic Acid | 2018 |
Alteration of macrophage viability, differentiation, and function by bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Cell Differentiation; Cell Survival; Diphosphonates; Humans; Macrophages; THP-1 Cells; Zoledronic Acid | 2018 |
Influence of pH on osteoclasts treated with zoledronate and alendronate.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Cells, Cultured; Dentin; Flow Cytometry; Hydrogen-Ion Concentration; In Vitro Techniques; Mice; Microscopy, Confocal; Microscopy, Electron, Scanning; Osteoclasts; Zoledronic Acid | 2019 |
Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human Primary Pre-Osteoblasts.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Calcification, Physiologic; Cell Differentiation; Cell Survival; Cells, Cultured; Collagen Type I; Cytokines; Humans; Osteoblasts; Osteopontin; Zoledronic Acid | 2019 |
Bisphosphonate combination therapy for non-femoral avascular necrosis.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteonecrosis; Prospective Studies; Young Adult; Zoledronic Acid | 2019 |
Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Humans; Incidence; Male; Mexico; Middle Aged; Osteoclasts; Retrospective Studies; Risedronic Acid; Time Factors; Zoledronic Acid | 2019 |
Review: Long-term alendronate or zoledronic acid reduces fractures in postmenopausal women with osteoporosis.
Topics: Alendronate; Female; Holidays; Humans; Osteoporosis; Postmenopause; Zoledronic Acid | 2019 |
Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model.
Topics: Administration, Oral; Alendronate; Animals; Anticarcinogenic Agents; Apoptosis; Azoxymethane; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Male; Metformin; Neoplasms, Experimental; Rats; Rats, Inbred F344; Zoledronic Acid | 2020 |
Impact of bisphosphonates on the proliferation and gene expression of human fibroblasts.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Differentiation; Cell Proliferation; Diphosphonates; Fibroblasts; Gene Expression Regulation; Humans; Ibandronic Acid; Jaw; Osteoblasts; Real-Time Polymerase Chain Reaction; Zoledronic Acid | 2019 |
Anti-tumor Activities of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors and Bisphosphonates in Pancreatic Cell Lines Which Show Poor Responses to Gemcitabine.
Topics: Alendronate; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Zoledronic Acid | 2020 |
Nonuraemic cutaneous calciphylaxis: our experience with a challenging disease.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calciphylaxis; Diphosphonates; Female; Humans; Kidney Failure, Chronic; Leg Ulcer; Male; Middle Aged; Outcome Assessment, Health Care; Transplants; Zoledronic Acid | 2020 |
Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Tooth Extraction; Wound Healing; Zoledronic Acid | 2020 |
Bisphosphonates in the management of Paget's disease.
Topics: Alendronate; Diphosphonates; Humans; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2020 |
Drug-induced ocular inflammation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Brimonidine Tartrate; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Etanercept; Female; Humans; Imidazoles; Immune Checkpoint Inhibitors; Male; Middle Aged; Nivolumab; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Scleritis; Uveitis, Anterior; Vemurafenib; Zoledronic Acid | 2020 |
Influence of bisphosphonates on oral implantology: Sodium alendronate and zoledronic acid enhance the synthesis and activity of matrix metalloproteinases by gingival fibroblasts seeded on titanium.
Topics: Alendronate; Cells, Cultured; Diphosphonates; Fibroblasts; Gingiva; Matrix Metalloproteinases; Sodium; Titanium; Zoledronic Acid | 2021 |
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Spinal Fractures; Zoledronic Acid | 2021 |
Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Female; Humans; Japan; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality-Adjusted Life Years; Zoledronic Acid | 2021 |
Tissue-Nonspecific Alkaline Phosphatase (TNAP) as the Enzyme Involved in the Degradation of Nucleotide Analogues in the Ligand Docking and Molecular Dynamics Approaches.
Topics: Adenosine Triphosphate; Alendronate; Alkaline Phosphatase; Computational Biology; Diphosphates; Diphosphonates; Enzymes; Humans; Hydrogen Bonding; Ligands; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Pamidronate; Phosphates; Protein Conformation; Thermodynamics; Zoledronic Acid | 2021 |
In vivo and in vitro analysis in a rat model using zoledronate and alendronate medication: microbiological and scanning electron microscopy findings on peri-implant rat tissue.
Topics: Alendronate; Animals; Dental Implants; Humans; Microscopy, Electron, Scanning; Rats; Surface Properties; Titanium; Zoledronic Acid | 2021 |
The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Denosumab; Female; Humans; Male; Osteoporosis; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2022 |
Host inflammatory response and clinical parameters around implants in a rat model using systemic alendronate and zoledronate acid drug administrations.
Topics: Alendronate; Animals; Dental Implants; Inflammation; Interleukin-6; Metal Nanoparticles; Osseointegration; Rats; Rats, Sprague-Dawley; Titanium; Tumor Necrosis Factor-alpha; Zirconium; Zoledronic Acid | 2022 |
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid | 2022 |
Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Taiwan; Teriparatide; Zoledronic Acid | 2022 |
Medication-Related Osteonecrosis of the Jaw: 14 Years' Retrospective Study on Pathogenetic Trigger Events.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Precipitating Factors; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2022 |
Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Female; Humans; Male; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid | 2023 |
Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study.
Topics: Alendronate; Bone Density Conservation Agents; Coronary Artery Disease; Diphosphonates; DNA-Binding Proteins; Humans; Osteoporosis; Pharmacovigilance; Teriparatide; Zoledronic Acid | 2023 |
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Diphosphonates; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2023 |
Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Medicare; Osteoporosis; Osteoporosis, Postmenopausal; Retrospective Studies; United States; Zoledronic Acid | 2023 |
Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Incidence; Osteoporosis; Pharmacovigilance; Risedronic Acid; Risk Factors; Zoledronic Acid | 2023 |
The real-world adherence of the first-line anti-osteoporosis medications in Taiwan: Visualize the gap between reality and expectations.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Humans; Medication Adherence; Motivation; Osteoporosis; Retrospective Studies; Taiwan; Zoledronic Acid | 2023 |
Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Denosumab; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Quality-Adjusted Life Years; Teriparatide; Zoledronic Acid | 2023 |
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid | 2023 |
The bisphosphonates alendronate and zoledronate induce adaptations of aerobic metabolism in permanent human endothelial cells.
Topics: Alendronate; Antioxidants; Diphosphonates; Endothelial Cells; Humans; Zoledronic Acid | 2023 |
Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2023 |